Should the last be first? Questions and dilemmas regarding early short-term insulin treatment in Type 2 Diabetes Mellitus

References

• Osei K. Global epidemic of type 2 diabetes: implications for developing countries. Ethn Dis. 2003;13:S102–6.
   PubMedGoogle Scholar
• Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 2014;383:1068–1083.
   PubMed Web of Science ®Google Scholar
• De Pablos-Velasco P, Parhofer KG, Bradley C, et al. Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA study. Clin Endocrinol (Oxf). 2014;80:47–56.
   PubMed Web of Science ®Google Scholar
• Khunti K, Wolden ML, Thorsted BL, et al. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013;36:3411–3417.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853.
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589.
   PubMed Web of Science ®Google Scholar
• Genuth S, Eastman R, Kahn R, et al. Implications of the United Kingdom prospective diabetes study. Diabetes Care. 2003;26:S28–32.
   PubMed Web of Science ®Google Scholar
• Ihnat MA, Thorpe JE, Ceriello A. Hypothesis: the ‘metabolic memory’, the new challenge of diabetes. Diabet Med. 2007;24:582–586.
   PubMed Web of Science ®Google Scholar
• Donath MY, Ehses JA, Maedler K, et al. Mechanisms of beta-cell death in type 2 diabetes. Diabetes. 2005;54:S108–13.
   PubMed Web of Science ®Google Scholar
• Mays L. Diabetes mellitus standards of care. Nurs Clin North Am. 2015;50:703–711.
   PubMed Web of Science ®Google Scholar
• Weng J, Retnakaran R, Ariachery CA, et al. Short-term intensive insulin therapy at diagnosis in type 2 diabetes: plan for filling the gaps. Diabetes Metab Res Rev. 2015;31:537–544.
   PubMed Web of Science ®Google Scholar
• Owens DR. Clinical evidence for the earlier initiation of insulin therapy in type 2 diabetes. Diabetes Technol Ther. 2013;15:776–785.
   PubMed Web of Science ®Google Scholar
• Li Y, Xu W, Liao Z, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care. 2004;27:2597–2602.
   PubMed Web of Science ®Google Scholar
• Ilkova H, Glaser B, Tunckale A, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care. 1997;20:1353–1356.
   PubMed Web of Science ®Google Scholar
• Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care. 2004;27:1028–1032.
   PubMed Web of Science ®Google Scholar
• Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet. 2008;371:1753–1760.
   PubMed Web of Science ®Google Scholar
• Chen HS, Wu TE, Jap TS, et al. Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care. 2008;31:1927–1932.
   PubMed Web of Science ®Google Scholar
• Matthews D, Hosker J, Rudenski A, et al. Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419.
   PubMed Web of Science ®Google Scholar
• Chon S, Rhee SY, Ahn KJ, et al. Long-term effects on glycaemic control and β-cell preservation of early intensive treatment in patients with newly diagnosed type 2 diabetes: a multicentre randomized trial. Diabetes Obes Metab. 2018;20:1121–1130.
   PubMed Web of Science ®Google Scholar
• Abdul-Ghani MA, Jenkinson CP, Richardson DK, et al. Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the veterans administration genetic epidemiology study. Diabetes. 2006;55:1430–1435.
   PubMed Web of Science ®Google Scholar
• Liu L, Ke W, Wan X, et al. Insulin requirement profiles of short-term intensive insulin therapy in patients with newly diagnosed type 2 diabetes and its association with long-term glycemic remission. Diabetes Res Clin Pract. 2015;108:250–257.
   PubMed Web of Science ®Google Scholar
• Kramer CK, Zinman B, Retnakaran R. Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2013;1:28–34.
   PubMed Web of Science ®Google Scholar
• Turner RC, McCarthy ST, Holman RR, et al. Beta-cell function improved by supplementing basal insulin secretion in mild diabetes. Br Med J. 1976;1:1252–1254.
   PubMed Web of Science ®Google Scholar
• Niswender KD. Basal insulin: beyond glycemia. Postgrad Med. 2011;123:27–37.
   PubMed Web of Science ®Google Scholar
• Dandona P, Aljada A, Mohanty P, et al. Insulin inhibits intranuclear factor kB and stimulates IkB in mononuclear cells in obese subjects: evidence for an anti-infammatory effect? J Clin Endocrinol Metab. 2001;86:3257–3265.
   PubMed Web of Science ®Google Scholar
• Chen H, Ren A, Hu S, et al. The significance of tumor necrosis factor-alpha in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Res Clin Pract. 2007;75:327–332.
   PubMed Web of Science ®Google Scholar
• Schaschkow A, Mura C, Dal S, et al. Impact of the type of continuous insulin administration on metabolism in a diabetic rat model. J Diabetes Res. 2016;2016:8310516.
   PubMedGoogle Scholar
• Chen X, Yu QQ, Zhu YH, et al. Insulin therapy stimulates lipid synthesis and improves endocrine functions of adipocytes in dietary obese C57BL/6 mice. Acta Pharmacol Sin. 2010;31:341–346.
   PubMed Web of Science ®Google Scholar
• Sun W, Bi Y, Liang H, et al. Inhibition of obesity-induced hepatic ER stress by early insulin therapy in obese diabetic rats. Endocrine. 2011;39:235–241.
   PubMed Web of Science ®Google Scholar
• Xu W, Weng J. Current role of short-term intensive insulin strategies in newly diagnosed type 2 diabetes. J Diabetes. 2013;5:268–274.
   PubMed Web of Science ®Google Scholar
• Skovsø S, Damgaard J, Fels JJ, et al. Effects of insulin therapy on weight gain and fat distribution in the HF/HS- STZ rat model of type 2 diabetes. Int J Obes (Lond). 2015;39:1531–1538.
   PubMed Web of Science ®Google Scholar
• Huang X, Li S, Yang M, et al. The effects of short-term continuous subcutaneous insulin infusion treatment on fasting glucagon-like peptide-1 concentrations in newly diagnosed type 2 diabetes. Diabetes Res Clin Pract. 2018;138:246–252.
   PubMed Web of Science ®Google Scholar
• Choi H, Kramer CK, Zinman B, et al. Effect of short-term intensive insulin therapy on the incretin response in early type 2 diabetes. Diabetes Metab. 2018 published online 2018 Jan 11. DOI:10.1016/j.diabet.2018.01.003
   Google Scholar
• DeVries JH, Siegelaar S, Holleman F, et al. Intensive insulin therapy in patients with type 2 diabetes. Lancet. 2008;372:717.
   PubMedGoogle Scholar
• Kramer CK, Zinman B, Choi H, et al. Predictors of sustained drug-free diabetes remission over 48 weeks following short-term intensive insulin therapy in early type 2 diabetes. BMJ Open Diabetes Res Care. 2016;4:e000270.
   PubMed Web of Science ®Google Scholar
• Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22:1462–1470.
   PubMed Web of Science ®Google Scholar
• Mashitisho ML, Mashitisho BG. Early insulin therapy in patients with type 2 diabetes mellitus. J Endocrinol Metab Diab South Africa. 2016;21:13–15.
   Web of Science ®Google Scholar
• Gerstein HC, Bosch J, ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319–328.
   PubMed Web of Science ®Google Scholar
• Stein CM, Kramer CK, Zinman B, et al. Clinical predictors and time course of the improvement in β-cell function with short-term intensive insulin therapy in patients with type 2 diabetes. Diabet Med. 2015;32:645–652.
   PubMed Web of Science ®Google Scholar
• Houlden R, Ross S, Harris S, et al. Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of type 2 diabetes: the Canadian INSIGHT study. Diabetes Res Clin Pract. 2007;78:254–258.
   PubMed Web of Science ®Google Scholar
• Secrest MH, Udell JA, Filion KB. The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors. Trends Cardiovasc Med. 2017;27:194–202.
   PubMed Web of Science ®Google Scholar
• Dandona P, Mohanty P, Chaudhuri A, et al. Insulin infusion in acute illness. J Clin Invest. 2005;115:2069–2072.
   PubMed Web of Science ®Google Scholar
• Dandona P, Chaudhuri A, Ghanim H, et al. Proinflammatory effects of glucose and anti-inflammatory effect of insulin: relevance to cardiovascular disease. Am J Cardiol. 2007;99:15B–26B.
   PubMed Web of Science ®Google Scholar
• Cosmi F, Shen L, Magnoli M, et al. Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. Eur J Heart Fail. 2018;20:888–895.
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Frier BM, Pistrosch F. Hypoglycemia and cardiovascular risk: is there a major link? Diabetes Care. 2016;39:S205–9.
   PubMed Web of Science ®Google Scholar
• Feldman-Billard S, Larger É, Massin P, et al. Early worsening of diabetic retinopathy after rapid improvement of blood glucose control in patients with diabetes. Diabetes Metab. 2018;44:4–14.
   PubMed Web of Science ®Google Scholar
• Holman RR, Farmer AJ, Davies MJ, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361:1736–1747.
   PubMed Web of Science ®Google Scholar
• Mu PW, Chen YM, Lu HY, et al. Effects of a combination of oral anti-diabetes drugs with basal insulin therapy on b-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes. Diabetes Metab Res Rev. 2012;28:236–240.
   PubMed Web of Science ®Google Scholar
• Raz I, Mosenzon O. Early insulinization to prevent diabetes progression. Diabetes Care. 2013;36:S190–7.
   PubMed Web of Science ®Google Scholar
• Harrison LB, Adams-Huet B, Raskin P, et al. Beta-cell function preservation after 3.5 years of intensive diabetes therapy. Diabetes Care. 2012;35:1406–1412.
   PubMed Web of Science ®Google Scholar
• Koufakis T, Ioannidis I, Zebekakis P, et al. The beta-cell death in long-term type 2 diabetes mellitus: never say never again. Minerva Endocrinol. 2018 published online 2018 May 28. DOI:10.23736/S0391-1977.18.02852-3
   PubMedGoogle Scholar
• Retnakaran R, Choi H, Ye C, et al. Two-year trial of intermittent insulin therapy vs metformin for the preservation of β-cell function after initial short-term intensive insulin induction in early type 2 diabetes. Diabetes Obes Metab. 2018;20:1399–1407.
   PubMed Web of Science ®Google Scholar
• Retnakaran R, Shen S, Hanley AJ, et al. Hyberbolic relationship between insulin secretion and sensitivity on oral glucose tolerance test. Obesity. 2008;16:1901–1907.
   PubMed Web of Science ®Google Scholar
• Peters AL, Davidson MB. Maximal dose glyburide therapy in markedly symptomatic patients with type 2 diabetes: a new use for an old friend. J Clin Endocrinol Metab. 1996;81:2423–2427.
   PubMed Web of Science ®Google Scholar
• Davidson MB. Pro’s and con’s of the early use of insulin in the management of type 2 diabetes: a clinical evaluation. Curr Opin Endocrinol Diabetes Obes. 2009;16:107–112.
   PubMed Web of Science ®Google Scholar
• Davidson MB. Early insulin therapy for type 2 diabetic patients: more cost than benefit. Diabetes Care. 2005;28:222–224.
   PubMed Web of Science ®Google Scholar
• Meneghini LF. Early Insulin treatment in type 2 diabetes. Diabetes Care. 2009;32:S266–9.
   PubMedGoogle Scholar
• Kunt T, Snoek FJ. Barriers to insulin initiation and intensification and how to overcome them. Int J Clin Pract Suppl. 2009;164:6–10.
   PubMedGoogle Scholar
• Schwartz SS, Epstein S, Corkey BE, et al. The time is right for a new classification system for diabetes: rationale and implications of the β-cell-centric classification schema. Diabetes Care. 2016;39:179–186.
   PubMed Web of Science ®Google Scholar
• Ahlqvist E, Storm P, Käräjämäki A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 2018;6:361–369.
   PubMed Web of Science ®Google Scholar